SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Care-plan review) — Muhammad Ali — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientMuhammad Ali
Date of birth1942-01-17
IdentifiersMRN HR-BX001-SYN-TD; SSN (made up) 000-01-7724
Document date1996-09-08
AuthorCeleste Moreau, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month Parkinson's disease review. [S]

History of Present Illness

Mr. Ali returns six months after his first visit. He continues carbidopa-levodopa one and a half tablets three times a day before meals, with phone alarms, and has noticed no wearing-off, involuntary movements, or lightheadedness. He finished physical therapy and keeps up about 180 minutes a week of walking, stationary cycling, and balance exercises. He practices his voice exercises daily. He has had no falls. When asked about impulse control today, he reports no new urges to gamble, shop, or eat and no compulsive hobbies. He has not yet seen a dentist. [S]

ElementDetail
MedicinesLevodopa 150 mg three times daily before meals; no side effects
Motor complicationsNone
ExerciseAbout 180 minutes a week
FallsNone in six months
Impulse controlNo new urges or compulsive behaviors

Review of Systems

SystemResultFinding
CardiovascularNegativeNo lightheadedness on standing or fainting
GastrointestinalNegativeNo constipation, nausea, or trouble swallowing
NeurologicalPositiveMild slowness and right-hand tremor, unchanged since the spring
PsychiatricNegativeMood good; no hallucinations or impulse-control problems

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Carbidopa-levodopa 25/100 mg oral tablet, one tablet by mouth three times dailyOne tablet by mouth three times daily, at about 7 a.m., noon, and 5 p.m.Oral route1984-10-01 to 1996-03-10completedS
Carbidopa-levodopa 25/100 mg oral tablet, one and a half tablets by mouth three times daily, 30 minutes before mealsOne and a half tablets (levodopa 150 mg) by mouth three times daily, 30 minutes before mealsOral route1996-03-10activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1996-09-08Body height191cmS
1996-09-08Body weight101kgS
1996-09-08Body mass index (BMI) [Ratio]27.7kg/m2S
1996-09-08Systolic blood pressure126mm[Hg]S
1996-09-08Diastolic blood pressure78mm[Hg]S
1996-09-08Heart rate70/minS
1996-09-08Respiratory rate14/minS
1996-09-08Body temperature36.6CelS
1996-09-08Oxygen saturation in Arterial blood by Pulse oximetry98%S

Physical Exam

Vital signs recorded on 1996-09-08; see the Vital Signs section. [S]

SystemFinding
GeneralAlert and engaged; voice clear in conversation
CardiovascularRegular rhythm at 70 per minute. Blood pressure 128/80 mmHg supine and 120/78 mmHg after 3 minutes standing, without symptoms; no orthostatic hypotension
NeurologicalOn state: MDS-UPDRS Part III 24; Hoehn and Yahr stage 2.5; no dyskinesia
GaitRecovers after two steps on the pull test; Timed Up and Go 11 seconds

Problems

ProblemClinical statusVerificationCodeProvenance
Parkinson's disease, young onset (diagnosed at 42), Hoehn and Yahr stage 2.5, without dyskinesia or motor fluctuationsactiveconfirmed G20.A1S — Synthetic modern coding of the publicly disclosed diagnosis; the stage and the absence of motor complications are synthetic.
Hypokinetic dysarthria with soft speech due to Parkinson's diseaseactiveconfirmed R47.1S — Synthetic modern coding of the publicly reported speech difficulty; the severity is synthetic.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationMDS-UPDRS Parts III and IV and Hoehn and Yahr stageEvery visitCompleted todayPart III 24, unchanged; Hoehn and Yahr 2.5; Part IV: no motor complications
ExaminationOrthostatic blood pressure, supine and after 3 minutes standingEvery visit while on dopaminergic treatmentCompleted today128/80 mmHg supine and 120/78 mmHg at 3 minutes standing; no orthostatic hypotension
Medication safetyDopaminergic regimen review for wearing-off, dyskinesia, and on-offEvery visitCompleted todayNo wearing-off or dyskinesia; no change
Medication safetyAvoidance of dopamine-blocking drugsEvery visitCompleted todayNo dopamine-blocking drugs
Medication safetyMedication side effects and adherenceEvery visitCompleted todayNo side effects or missed doses
ExaminationFall query and fall-risk assessment (Timed Up and Go, pull test)Every visitCompleted todayNo falls in six months; Timed Up and Go 11 seconds
SurveyPsychotic symptoms (hallucinations, delusions)Every visitCompleted todayNone
SurveyImpulse-control screen (QUIP-RS)Every visit; mandatory on a dopamine agonistCompleted todayNegative; the screen missed at three months was done today
Self-managementExercise counseling: aerobic, resistance, and balance, at least 150 minutes a weekEvery visitCompleted todayAbout 180 minutes a week
Self-managementAdvance care planning and goals of careAt diagnosis and at least yearlyDueAt the preventive visit next month
ExaminationDiagnosis review against the MDS clinical diagnostic criteriaYearlyUp to dateConfirmed by neurology six months ago; next review in the spring
SurveyCognitive screen (MoCA)At least yearlyUp to dateMoCA 27 of 30 seven months ago
SurveyDepression, anxiety, and apathy (PHQ-9)At least yearlyUp to datePHQ-9 3 seven months ago; mood good today; depression screen at the preventive visit
SurveySleep: REM sleep behavior disorder questionnaire, Epworth Sleepiness Scale, insomnia, restless legsAt least yearlyUp to dateNo dream enactment or daytime sleepiness
SurveyAutonomic symptoms: constipation, urinary, sexual, sweating, droolingAt least yearlyUp to dateNo autonomic symptoms
SurveySwallowing screen (EAT-10)At least yearlyUp to dateNo choking or coughing with meals; EAT-10 due at the first visit next year
ExaminationSpeech and voice loudnessYearly; speech therapy for speech changeUp to dateGains maintained with daily practice
ReferralPhysical, occupational, and speech therapyAt diagnosis, then reassessed yearlyUp to datePhysical therapy and speech therapy completed; reassess yearly
LaboratoryGenetic testing with counselingOnce, offered to every person with Parkinson's diseaseDueDecision at the yearly neurology review
ExaminationDental and oral examinationEvery 6 monthsDeferredNo dental examination in the six months since the first visit, a deviation from the protocol. He has no drooling, mouth pain, or chewing problems, so no harm is evident. Corrective action: a dental appointment is to be arranged at the preventive visit next month
ExaminationDriving safetyYearly or with a motor or cognitive changeUp to dateNo change; review at the first visit next year
Self-managementVaccination status (influenza, pneumococcal, zoster, COVID-19, Tdap)Yearly, per the CDC scheduleDueInfluenza, pneumococcal, and zoster vaccines at the preventive visit next month
LaboratoryRoutine laboratory monitoringNot required for Parkinson's disease surveillanceNot indicatedThe CMID monograph calls for no routine laboratory tests; baseline blood count, chemistry, vitamin B12, and TSH were normal at the first visit
ImagingBrain MRIIf atypical parkinsonism features appearNot indicatedNo atypical features; examination stable
ImagingPolysomnography for REM sleep behavior disorderIf REM sleep behavior disorder treatment is consideredNot indicatedNo dream enactment
Medication safetyAGS Beers Criteria medication reviewYearly from age 65Not indicatedHe is 54
ExaminationDeep brain stimulation programming reviewEvery 6 to 12 months after implantationNot indicatedNo deep brain stimulator

Goal progress:

Guideline basis: Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee (2021); MDS clinical diagnostic criteria for Parkinson's disease (2015); The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension (2017); CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026)

Follow-up: Periodic preventive visit in four weeks, with vaccines, advance care planning, and the dental appointment. Quarterly Parkinson's disease review in three months. Next scheduled visit 1996-10-06: periodic adult preventive visit. [S]